A Phase II Neo-adjuvant Study Assessing TCH (Docetaxel, Carboplatin and Trastuzumab) and TCHL (Docetaxel, Carboplatin, Trastuzumab and Lapatinib) in HER-2 Positive Breast Cancer Patients.

NCT01485926 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

120

Enrollment

NETWORK

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Docetaxel, Carboplatin and Trastuzumab
DRUG: Docetaxel, Carboplatin, Trastuzumab and Lapatinib

Sponsor

Cancer Trials Ireland